Literature DB >> 27426958

The role of vascular endothelial growth factor -634 G/C and its soluble receptor on chronic liver disease and hepatocellular carcinoma.

Neneng Ratnasari1, Siti Nurdjanah2, Ahmad H Sadewa3, Mohammad Hakimi4.   

Abstract

BACKGROUND AND STUDY AIMS: The single nucleotide polymorphism (SNP) of the vascular endothelial growth factor (VEGF) gene -634 G/C (rs2010963) influences the progression of hepatocellular carcinoma (HCC). There have been no studies on the role of VEGF SNP -634 G/C in chronic liver disease (CLD). The aim of the present study was to analyse the correlation between VEGF SNP -634 and the clinical severity of CLD and HCC. PATIENTS AND METHODS: A cross sectional study was conducted on 182 subjects (46 HCC, 39 liver cirrhotic/LC, 38 chronic hepatitis/CH; and 57 healthy subjects). The study was conducted from 2010 to 2014 at the Dr. Sardjito Hospital Yogyakarta, Indonesia. All subjects submitted blood serum for DNA sequencing examination using primer. The clinical data of CLD and HCC were assessed, and sVEGFR-2 was examined in 149 subjects. All data were analysed using STATA programme 11.0.
RESULTS: Significant differences were observed in genotypic frequency (GG/GC/CC) between HCC, LC, CH and healthy subjects (p=0.004), but though no significant differences were observed between the G>G and C>G genotypic frequencies (p=0.337). The frequency of genotype GG was significantly higher than genotype GC or CC in HCC and was associated with declining of clinical conditions (p<0.05). No significant difference in the distribution genotypes was observed with respect to the level of sVEGFR-2 in the serum. However, we observed a significant correlation between sVEGFR-2 and clinical characteristics in LC and CH (p<0.05).
CONCLUSION: Genotype GG of the VEGF SNP -634 is the dominant genotype in severe CLD and HCC. sVEGFR-2 correlates with the disease severity but is not directly associated with the SNP -634 genotype.
Copyright © 2016 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic liver disease; Hepatocellular carcinoma; VEGF −634 G/C; sVEGFR-2

Mesh:

Substances:

Year:  2016        PMID: 27426958     DOI: 10.1016/j.ajg.2016.06.005

Source DB:  PubMed          Journal:  Arab J Gastroenterol        ISSN: 1687-1979            Impact factor:   2.076


  8 in total

1.  Underexpression of miR-126-3p in Patients with Cholangiocarcinoma.

Authors:  Lucas Poleto Spinola; Gabriel F Vieira; Rafael Fernandes Ferreira; Maria C J Calastri; Graciele D Tenani; Franciana L Aguiar; Ilka F Santana Ferreira Boin; Larissa B E Da Costa; Maria Fernanda Chaim Correia; Eliane M Zanovelo; Daniele C B De Souza; Rita C Martins Alves Da Silva; Renato Ferreira Da Silva; Ana Margarida Coelho Abrantes; Maria Filomena R R Botelho; Jose Guilherme L R Tralhão; Doroteia R S Souza
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

2.  Quantitative assessment of HLA-DQ gene polymorphisms with the development of hepatitis B virus infection, clearance, liver cirrhosis, and hepatocellular carcinoma.

Authors:  Tao Xu; Anyou Zhu; Meiqun Sun; Jingzhu Lv; Zhongqing Qian; Xiaojing Wang; Ting Wang; Hongtao Wang
Journal:  Oncotarget       Date:  2017-12-05

3.  Difference of polymorphism VEGF-gene rs699947 in Indonesian chronic liver disease population.

Authors:  Neneng Ratnasari; Siti Nurdjanah; Ahmad Hamim Sadewa; Mohammad Hakimi; Yoshihiko Yano
Journal:  PLoS One       Date:  2017-08-24       Impact factor: 3.240

4.  Associations between twelve common gene polymorphisms and susceptibility to hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Yi Quan; Jun Yang; Tao Qin; Yufang Hu
Journal:  World J Surg Oncol       Date:  2019-12-12       Impact factor: 2.754

5.  Oxidative stress, immunological and cellular hypoxia biomarkers in hepatitis C treatment-naïve and cirrhotic patients.

Authors:  Abdulrahman Hamdan Almaeen; Abdulrahman Abdulwahab Alduraywish; Maysa Ahmed Mobasher; Omar I M Almadhi; Hanan M Nafeh; Tarek Hassan El-Metwally
Journal:  Arch Med Sci       Date:  2020-01-03       Impact factor: 3.318

6.  Methylene tetrahydrofolate reductase (MTHFR) and vascular endothelial growth factor (VEGF) polymorphisms in Brazilian patients with Hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC).

Authors:  Sylene C R Carvalho; Luydson R S Vasconcelos; Leonardo da Fonseca; Rodrigo F Carmo; Michele T Tomitão; Dayse C B L Aroucha; Leila M M B Pereira; José Tadeu Stefano; Ulysses Ribeiro-Júnior; Claudia P Oliveira; Flair J Carrilho
Journal:  Clinics (Sao Paulo)       Date:  2021-10-11       Impact factor: 2.365

7.  Interaction Between Vascular Endothelial Growth Factor Gene Polymorphism and Smoking on Gastric Cancer Risk in Chinese Han Population.

Authors:  Longyue Wang; Shuaishuai Xiao; Yiming Zheng; Zefeng Gao
Journal:  Pathol Oncol Res       Date:  2022-08-25       Impact factor: 2.874

8.  Association of Vascular Endothelial Growth Factor ( VEGF) Gene Polymorphisms With Gastric Cancer and Its Development, Prognosis, and Survival.

Authors:  Weimin Liu; Zhiyong Dong; Ruixiang Hu; Cunchuan Wang
Journal:  Technol Cancer Res Treat       Date:  2018-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.